melanoma

News

MSD has another TIGIT programme setback

A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi

News

New era for cell therapy as FDA OKs first for solid tumours

Iovance Biotherapeutics has carved out a piece of biotech history, becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour.

News

FDA clears AI skin cancer detection device from DermaSensor

Medtech company DermaSensor has claimed FDA approval for a handheld device, powered by artificial intelligence (AI), that can be used to detect skin cancer at the point of

News

MSD, Moderna cancer vaccine aces melanoma study

MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma.

News

Daiichi Sankyo unit claims $182m in Novartis patent dispute

Novartis has settled a lawsuit brought by Daiichi Sankyo’s Plexxikon subsidiary, paying $180 million to resolve claims that its Tafinlar cancer drug infringed US patents h

News

FDA capacity forces delay to Iovance's cell therapy

Iovance Biotherapeutics is facing a three-month delay in the review of its lifileucel cell therapy for melanoma in the US, held up by "insufficient resources" at the FDA.

MSD has another TIGIT programme setback

New era for cell therapy as FDA OKs first for solid tumours

FDA clears AI skin cancer detection device from DermaSensor

MSD, Moderna cancer vaccine aces melanoma study

Daiichi Sankyo unit claims $182m in Novartis patent dispute

FDA capacity forces delay to Iovance's cell therapy

Late-breakers to look out for at ASCO 2026

Discover a new era of healthcare panel engagement: Grounded ...

melanoma

Editor's Picks